
CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 500 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK4/6-IN-8
CAS:<p>CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM).</p>Formula:C18H18N6O5Color and Shape:SolidMolecular weight:398.37AS-0141
CAS:<p>AS-0141 (Cdc7-IN-6) 是一种有效的 Cdc7 激酶抑制剂 (IC50=4 nM),具有抗肿瘤活性。Cdc7 是一种丝氨酸苏氨酸蛋白激酶酶,在细胞周期中对 DNA 复制的启动至关重要。</p>Formula:C21H22F3N5O4Purity:99.97%Color and Shape:SolidMolecular weight:465.43Ryuvidine
CAS:<p>Ryuvidine is a dual inhibitor of KDM5A and SETD8, an inducer of the DNA damage response, and can be used to study breast cancer and erythroderma.</p>Formula:C15H12N2O2SPurity:98.6%Color and Shape:SolidMolecular weight:284.33(S)-Enitociclib
CAS:<p>(S)-Enitociclib (VIP152) is a selective CDK9 inhibitor that inhibits the transcription of anti-apoptotic and pro-survival proteins.</p>Formula:C19H18F2N4O2SPurity:98.98%Color and Shape:SolidMolecular weight:404.43CLK-IN-T3
CAS:<p>CLK-IN-T3 is an inhibitor of CLK1, CLK2, and CLK3 with IC50s of 0.67, 15, and 110 nM. CLK-IN-T3 exhibits anti-cancer activity.</p>Formula:C28H30N6O2Purity:99.61%Color and Shape:SolidMolecular weight:482.58(S)-PF-06873600
CAS:<p>(S)-PF-06873600 is the S enantiomer of PF-06873600 which is an inhibitor of CDK.</p>Formula:C20H27F2N5O4SPurity:98.59%Color and Shape:SolidMolecular weight:471.52CDK9-IN-10
CAS:<p>CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.</p>Formula:C22H16O5Purity:99.8%Color and Shape:SolidMolecular weight:360.36PS423
CAS:<p>PS423 is a substrate-selective protein kinase PDK1 inhibitor that acts by binding to the PIF-pocket allosteric docking site.</p>Formula:C25H23F3O9Purity:98.81% - 99.26%Color and Shape:SolidMolecular weight:524.44HTH-01-091
CAS:<p>HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM).HTH-01-091 inhibits PIM1/2/3, RIPK2, DYRK3,</p>Formula:C26H28Cl2N4O2Purity:98.4%Color and Shape:SolidMolecular weight:499.43hSMG-1 inhibitor 11e
CAS:<p>hSMG-1 inhibitor 11e is an effective and selective inhibitor of hSMG-1 (IC50 <0.05 nM) and can be used in studies about cancer treatment.</p>Formula:C26H27N7O3SPurity:99.89%Color and Shape:SolidMolecular weight:517.6CDK-IN-2
CAS:<p>CDK-IN-2 (CDK inhibitor II) is a potent and specific CDK9 inhibitor (IC50: <8 nM).</p>Formula:C18H19ClFN3O2Purity:99.67%Color and Shape:SolidMolecular weight:363.819-Isopropylolomoucine
CAS:<p>9-Isopropylolomoucine (N9-Isopropylolomoucine), a cell cycle protein-dependent kinase inhibitor, is a thiopurine.</p>Formula:C17H22N6OPurity:99.82%Color and Shape:SolidMolecular weight:326.4CDK8-IN-1
CAS:<p>CDK8-IN-1 is a selective CDK8 inhibitor (IC50: 3 nM).</p>Formula:C11H8F3N3OPurity:98.48%Color and Shape:SolidMolecular weight:255.2Cdc7-IN-7c
CAS:<p>Cdc7-IN-7c (Cdc7 inhibitor-7c) has antitumor activity and has inhibitory effect on liver cancer, lung cancer, kidney cancer, brain cancer and cervical cancer.</p>Formula:C15H17N5OSPurity:98.19% - 99.22%Color and Shape:SolidMolecular weight:315.39SEL120-34A
CAS:<p>SEL120-34A inhibits CDK8 (IC50: 4.4 nM) & CDK19 (10.4 nM), less on CDK9 (1070 nM), has antitumor properties.</p>Formula:C15H18Br2N4Purity:99.764% - 99.84%Color and Shape:SolidMolecular weight:414.14CDK4/6/1 Inhibitor
CAS:<p>CDK4/6/1 Inhibitor (Crozbaciclib) is a type of CDK4/6 inhibitor (IC50s: 3 and 1 nM).</p>Formula:C28H30F2N6Purity:99.26% - 99.72%Color and Shape:SolidMolecular weight:488.57BML-259
CAS:<p>BML-259 inhibits CDK5/CDK2 (IC50: 64/98 nM) for cancer and neurodegeneration research.</p>Formula:C14H16N2OSPurity:99.84%Color and Shape:SolidMolecular weight:260.35dCeMM2
CAS:<p>dCeMM2 degrades glue by promoting CDK12-cyclin K ubiquitination and degradation via CRL4B ligase interaction.</p>Formula:C16H11ClN6OSPurity:99.68%Color and Shape:SolidMolecular weight:370.82Cdk2 Inhibitor II
CAS:<p>Cdk2 Inhibitor II is a selective and potent CDK2 inhibitor50 at 60 nM.</p>Formula:C14H11BrN4O3SPurity:97.07%Color and Shape:SolidMolecular weight:395.23Abemaciclib metabolite M20
CAS:<p>Abemaciclib metabolite M20 (CDK4/6-IN-4) 是 Abemaciclib 的活性代谢物。 Abemaciclib metabolite M20 是一种特异性 CDK4/6 抑制剂,可用于癌症治疗的相关研究。</p>Formula:C27H32F2N8OPurity:98.1% - 99.08%Color and Shape:SolidMolecular weight:522.59SHP2/CDK4-IN-1
CAS:<p>SHP2/CDK4-IN-1: dual inhibitor, oral, potent (IC50: SHP2 4.3 nM, CDK4 18.2 nM), hinders TNBC growth, strong antitumor effects in mice.</p>Formula:C33H35ClF2N10OSColor and Shape:SolidMolecular weight:693.21CDK-IN-11
CAS:<p>CDK-IN-11, a heterocyclic compound, promotes cardiomyocyte maturation [1].</p>Formula:C25H21BrN4O2Color and Shape:SolidMolecular weight:489.36CDK/HDAC-IN-3
CAS:<p>CDK/HDAC-IN-3 is an orally active dual inhibitor of HDACs and CDKs, offering potent and selective inhibition of CDK9, CDK12, CDK13, HDAC1, HDAC2, and HDAC3,</p>Formula:C24H18Cl2N6O3Purity:98%Color and Shape:SolidMolecular weight:509.34Cdk4 Inhibitor
CAS:<p>PD 0332991, an unsymmetrical indolocarbazole compound, is cell-permeable and exhibits antiproliferative effects by functioning as a potent, selective, reversible, and ATP-competitive inhibitor of Cdk4/D1 (IC 50 = 76 nM). Although it can inhibit other Cdks, such as Cdk2/E and Cdk1/B, effectiveness requires higher concentrations (IC 50 = 520 nM and 2.1 µM, respectively) and demonstrates minimal activity against CaMKII, PKA, or GSK-3β (IC 50 ≥ 12.4 µM). PD 0332991 efficiently inhibits tumor cell growth in HCT-116 and NCI-H460 cell lines with an IC 50 < 3.0 µM, primarily through blocking Rb phosphorylation and inducing G1 cell cycle arrest.</p>Formula:C20H10BrN3O2Color and Shape:SolidMolecular weight:404.2EHT 5372
CAS:<p>EHT 5372 inhibits DYRK kinases; IC50: 0.22-221 nM for DYRK1A/B, DYRK2/3, CLK1/2/4, GSK-3α/β.</p>Formula:C17H11Cl2N5OSColor and Shape:SolidMolecular weight:404.27Nε-(1-Carboxyethyl)-L-lysine
CAS:<p>Nε-(1-Carboxyethyl)-L-lysine (CEL) is an advanced glycation end-product (AGE). Exposure to CEL reduces glutamate uptake and S100B secretion in the hippocampus.</p>Formula:C9H18N2O4Color and Shape:SolidMolecular weight:218.25Lerociclib
CAS:<p>Lerociclib (G1T38) is a CDK4/6 inhibitor with anticancer and antitumor activities, inhibiting CDK4/CyclinD1 and CDK6/CyclinD3.</p>Formula:C26H34N8OPurity:99%Color and Shape:SolidMolecular weight:474.6CDK8-IN-3
CAS:<p>CDK8-IN-3 is an inhibitor of CDK8.</p>Formula:C22H23N5O2Purity:98%Color and Shape:SolidMolecular weight:389.45CDK9-IN-29
CAS:<p>CDK9-IN-29 (compound Z11) is a potent inhibitor of CDK9, exhibiting high kinase selectivity and an IC50 value of 3.20 nM.</p>Formula:C29H33F2N5O4Purity:98%Color and Shape:SolidMolecular weight:553.6IIIM-290
CAS:<p>IIIM-290 is an oral CDK inhibitor (IC50s: 90 and 94 nM for CDK2/A and CDK9/T1).</p>Formula:C23H21Cl2NO5Purity:98%Color and Shape:SolidMolecular weight:462.32CCT-251921
CAS:<p>CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).</p>Formula:C21H23ClN6OPurity:99.07%Color and Shape:SolidMolecular weight:410.9CDK9-IN-8
CAS:<p>CDK9-IN-8 is a highly potent and selective CDK9 inhibitor (IC50: 12 nM).</p>Formula:C31H32FN7O3Purity:99.54%Color and Shape:SolidMolecular weight:569.63QR-6401
CAS:<p>QR-6401, a selective macrocyclic CDK2 inhibitor, is orally active with IC50 values of 0.37 nM for CDK2/E1, 10 nM for CDK9/T1, 22 nM for CDK1/A2, 34 nM for CDK6/</p>Formula:C19H23N5O3Purity:98%Color and Shape:SolidMolecular weight:369.42Tacaciclib
CAS:<p>Tacaciclib is a cyclin-dependent kinase (CDK) inhibitor with observed antineoplastic activity [1].</p>Formula:C30H36N6O3Purity:98%Color and Shape:SolidMolecular weight:528.65Mevociclib
CAS:<p>Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors.</p>Formula:C31H35ClN8O2Purity:98.02% - 98.02%Color and Shape:SolidMolecular weight:587.11Palbociclib orotate
CAS:<p>Palbociclib (PD 0332991) orotate, an orally active selective inhibitor of CDK4 and CDK6, exhibits IC50 values of 11 and 16 nM, respectively.</p>Formula:C29H33N9O6Purity:98%Color and Shape:SolidMolecular weight:603.63KM05382
CAS:<p>KM05382 inhibits CDK9 and the transcription of GAPDH.</p>Formula:C20H19ClN2O3S2Color and Shape:SolidMolecular weight:434.96CDK4-IN-2
CAS:<p>CDK4-IN-2 (A17) is a potent inhibitor of CDK4, exhibiting K i and IC 50 values of less than 10 nM and is utilized in cancer research [1].</p>Formula:C22H26F2N6O4SPurity:98%Color and Shape:SolidMolecular weight:508.54DCB-3503
CAS:<p>DCB-3503, a tylophorine analog, may fight cancer and aid immunosuppression by hindering protein synthesis and modulating HSC70 ATPase function.</p>Formula:C24H27NO5Color and Shape:SolidMolecular weight:409.47LDC3140
CAS:<p>LDC3140 is a potent inhibitor of Cyclin-dependent kinase 7 (CDK7).</p>Formula:C23H33N7OPurity:98%Color and Shape:SolidMolecular weight:423.55Leucettinib-92
CAS:<p>Leucettinib-92 (compound 92) is a kinase inhibitor selective for DYRK/CLK families, displaying IC50 values of 147 nM (CLK1), 39 nM (CLK2), 5.2 nM (CLK4), 0.8 μM</p>Formula:C21H22N4OSPurity:98%Color and Shape:SolidMolecular weight:378.49CDK9-IN-9
CAS:<p>CDK9-IN-9 is a potent and selective CDK9 inhibitor (IC50: 1.8 nM) with anti-cancer activity. It inhibits CDK2 (IC50: 155 nM).</p>Formula:C22H23F2N5O2SPurity:98%Color and Shape:SolidMolecular weight:459.51(2S,3R)-Voruciclib
CAS:<p>(2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. It is an orally active CDK inhibitor.</p>Formula:C22H19ClF3NO5Purity:98%Color and Shape:SolidMolecular weight:469.84CDK9-IN-2
CAS:<p>CDK9-IN-2, a CDK9 inhibitor from patent WO/2012131594A1, IC50: 5 nM in A2058, 7 nM in H929 at 72hr.</p>Formula:C23H25ClFN5Purity:99%Color and Shape:SolidMolecular weight:425.93CDK7-IN-14
CAS:<p>CDK7-IN-14, a potent CDK7 inhibitor from pyrimidines, may treat transcriptionally dysregulated cancers (CN114249712A).</p>Formula:C22H24F3N6OPColor and Shape:SolidMolecular weight:476.435-Iodo-indirubin-3'-monoxime
CAS:<p>5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s</p>Formula:C16H10IN3O2Color and Shape:SolidMolecular weight:403.17NU6300
CAS:<p>NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties and also functions as a GSDMD (Gasdermin D) inhibitor.</p>Formula:C20H23N5O3SPurity:96.08%Color and Shape:SolidMolecular weight:413.49Voruciclib hydrochloride
CAS:<p>Voruciclib hydrochloride is an orally active and selective inhibitor of CDK (Ki: 0.626 nM-9.1 nM).</p>Formula:C22H20Cl2F3NO5Purity:98%Color and Shape:SolidMolecular weight:506.3PF-6808472
CAS:<p>PF-6808472 is a cell-permeable covalent kinase probe, reacts with conserved lysine residues within the ATP-binding site of kinases.</p>Formula:C25H27FN8O3SPurity:99.02%Color and Shape:SolidMolecular weight:538.6CDK7-IN-22
CAS:<p>CDK7-IN-22 (compound 101) is a selective CDK7 inhibitor that exhibits antitumor activity, demonstrating specificity for CDK7 [1].</p>Formula:C22H25F3N6Purity:98%Color and Shape:SolidMolecular weight:430.47

